Brief: Monte Rosa Therapeutics Announces Q4 And FY 2023 Financial Results
14/03/2024 12:07
March 14 (Reuters) - Monte Rosa Therapeutics Inc
GLUE.O :
* MONTE ROSA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL
YEAR
2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* STRONG CASH POSITION EXPECTED TO FUND OPERATIONS INTO H1
2026
* CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND MARKETABLE
SECURITIES AS OF DEC 31, 2023, WERE $237.0 MILLION
Source text for Eikon: ID:nGNX5YK3ZY
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million